Aristotle University Of Thessaloniki (AUTH)
Διερεύνηση της βέλτιστης θεραπευτικής προσέγγισης ανάμεσα στους αντι-TNFα, αντι-ΙL12/23, αντι-IL17 και αντι-IL23 βιολογικούς παράγοντες και την απρεμιλάστη σε ασθενείς με ψωρίαση σε δύσκολες-προς-αντιμετώπιση περιοχές και προσδιορισμός πιθανών προγνωστικών παραγόντων θεραπευτικής έκβασης
Abstract
dc:descriptionIntroduction: Plaque psoriasis is a chronic, inflammatory, systemic disease affecting the skin and the joints. Skin lesions, particularly in specific anatomical sites, such as the scalp, palms, soles, genital area and nails, significantly affect the patient's physical and psychological well-being. Despite the many available and effective treatments, under-treatment of psoriasis remains a significant issue, especially when the disease occurs in these special areas, which are often neglected. Aim: To provide an optimal therapeutic approach - in terms of biological agents and small molecules - in the daily clinical practice of patients with plaque psoriasis and, in particular, with disease localization on the scalp, nails, palms, soles and genital area. Methodology: This was a prospective, comparative, assessor-blinded, open-label cohort study. The study was conducted at the First Dermatology Department of the Aristotle University of Thessaloniki. In our study, we compared cohorts of adult patients receiving ixekizumab, brodalumab, guselkumab, risankizumab, secukinumab, ustekinumab, adalimumab, infliximab, etanercept, certolizumab pegol or apremilast. The efficacy and safety of the respective treatments overall in psoriasis, and by anatomical region, were evaluated at weeks 16, 24, 52, 62 and 78. Statistical analysis was performed by analysis of covariance (ANCOVA), logistic regression, univariate and multivariate analysis. Fisher's exact test was used for comparison where necessary. Descriptive statistics were performed with percentages, means and standard deviation. Results: A total of 568 adult patients were recruited. With regard to biological agents in general, in short-term efficacy (up to 24 weeks), the anti-interleukin (IL) 17 agents appeared superior to the other classes of biological agents in achieving both PASI 90 and PASI 100. At 16 weeks, the largest differences were observed between biological agents and apremilast, with the latter being inferior [Odds Ratio (OR): 1.76-5.03). Also, infliximab was significantly more effective (OR variance: 2.04-4.77) in the individual assessments. However, there was no statistically significant difference between infliximab, ixekizumab and risankizumab in terms of achieving PASI 90 (p < 0.05). At 24 weeks, the largest difference, excluding apremilast, was shown by infliximab from etanercept [OR: 4.62 (95% CI: 2.45-5.77)] and the most minor statistically significant difference by secukinumab from guselkumab [OR: 1.08 (95% CI: 1.06-2.13)]. In the long-term (up to 78 weeks), anti-IL-17 and anti-IL-23 agents proved more effective. In particular, risankizumab (52 weeks: RR: 1.73; 95% CI: 1.46-2.05; 62 weeks: RR: 1.78; 95% CI: 1.64-2.35; 78 weeks: RR: 1.62; 95% CI: 1.32-2.57), secukinumab (52 weeks: RR: 1.23; 95% CI: 1.15-1.31; 62 weeks: RR: 1.32; 95% CI: 1.24-2.13; 78 weeks: RR: 1.29; 95% CI: 1.03-2.13) and ixekizumab (52 weeks: RR: 1.30; 95% CI: 1.11-1.52; 62 weeks: 1.32; 95% CI: 1.18-2.45; 78 weeks: 1.27; 95% CI: 1.14-2.56) were the most effective treatment options. In terms of the special sites, the anti-IL-17 cohort was at least 50% more likely to achieve skin clearance in the scalp (16 weeks: OR: 1.53; 95% CI: 1.18-1.86; 24 weeks: OR: 1.48; 95% CI: 1.22-1.92), genitals (16 weeks: OR: 1.57; (16 WEEKS: 1.1: 1.2; 95% CI: 1.32-2.14; 24 weeks: OR: 1.51; 95% CI: 1.17-1.92), or the nails (16 weeks: OR: 1.92; 95% CI: 1.41-2.36; 24 weeks: OR: 2.13; 95% CI: 1.24-3.18) at weeks 16 and 24. Specifically, in the scalp, ixekizumab had the best results in complete clearance as early as 16 weeks (72.73%), followed by risankizumab (65.30%), and these rates increased at 24 weeks (81.82% and 79.59%, respectively). In genital psoriasis, secukinumab (16 weeks: 88.24%; 24 weeks: 94.12%) was preceded, followed closely by brodalumab (16 weeks: 84.62%; 24 weeks: 92.30%). In nails, the most effective were ixekizumab (16 weeks: 65.22%; 24 weeks: 73.91%) and secukinumab (16 weeks: 63.64%; 24 weeks: 72.73%). In palmoplantar psoriasis, apremilast in the short term had the best results in PPPASI 0/1 (16 weeks: 83.33%), but later on, ixekizumab (87.50%), brodalumab (86.67%) and risankizumab (84.62%) were more effective. In the long-term (up to 78 weeks), risankizumab achieved PSSI 0/1 in a higher percentage (97.96%) on the scalp, while, in the genital area, complete clearance reaching 100% of patients was achieved by risankizumab, ustekinumab, ixekizumab, brodalumab and guselkumab. Nails proved to be more resistant to treatment, with NAPSI 0/1 being maintained up to 78 weeks at a superior rate of 67.86% with risankizumab. Relatively low rates of PPPASI 0/1 retention up to 78 weeks were also observed, with the superior rate of retention in the secukinumab cohort (77.78%) followed by risankizumab (76.92%).Conclusion: The present study showed that infliximab, ixekizumab and risankizumab were the most effective treatments for achieving PASI 90 and PASI 100 in patients with moderate to severe plaque psoriasis. In terms of special sites, they appear to show excellent to fairly satisfactory response to modern therapies, with ixekizumab, brodalumab and risankizumab being the most rapid biological agents in skin clearance in these areas, even over time. However, long-term studies with a larger population are necessary to draw more definitive conclusions.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2024
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Bakirtzi, Aikaterini
- Μπακιρτζή, Αικατερίνη
Subjects
dc:subject × 8Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/57608